Peter S. Klein
CIK: 0001478007
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Jun 3, 2026DNLI
Denali Therapeutics Inc.
Award(A)Direct6.4K shares- - Jun 3, 2025DNLI
Denali Therapeutics Inc.
Award(A)Direct6K shares- - Apr 8, 2025ACCD
Accolade, Inc.
Disposition(D)Direct28.3K shares at avg. $7.03$199K - Mar 13, 2025FFIV
F5, INC.
Award(A)DirectRestricted Stock Unit
934 shares- - Mar 12, 2025FFIV
F5, INC.
Exercise(M)Direct1.3K shares- - Sep 5, 2024FFIV
F5, INC.
Gift(G)Direct1K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 3, 2026 |  DNLI Denali Therapeutics Inc. | Award(A) | 6,408 | - | $0 | Direct |
| Jun 3, 2025 | DNLI Denali Therapeutics Inc. | Award(A) | 6,037 | - | - | Direct |
| Apr 8, 2025 |  ACCD Accolade, Inc. | Disposition(D) | 28,329 | $7.03 | $199,153 | Direct |
| Mar 13, 2025 |  FFIV F5, INC. | Award(A) Restricted Stock Unit | 934 | - | - | Direct |
| Mar 12, 2025 | FFIV F5, INC. | Exercise(M) | 1,309 | - | - | Direct |
| Sep 5, 2024 | FFIV F5, INC. | Gift(G) | 1,000 | - | $0 | Direct |
1-6 of 6 transactions
About Klein Peter S
Klein Peter S (SEC CIK 0001478007) files insider reports with the SEC as Director of Denali Therapeutics Inc. (DNLI), Director of Accolade, Inc. (ACCD) and Director of F5, INC. (FFIV).
Signal8 holds 5 ownership filings by Klein Peter S, all Form 4s, filed between Sep 6, 2024 and Jun 5, 2026. Those filings report 6 transactions, from Sep 5, 2024 to Jun 3, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Klein Peter S's filings is in SOUTH SAN FRANCISCO, CA.
Recent filings by Klein Peter S
- Jun 3, 2026: Grant or award of DNLI shares (Form 4, code A).
- Jun 3, 2025: Grant or award of DNLI shares (Form 4, code A).
- Apr 8, 2025: Disposition to issuer transaction of ACCD shares (Form 4, code D).
- Mar 13, 2025: Grant or award of FFIV derivative securities (Form 4, code A).
- Mar 12, 2025: Option exercise of FFIV shares (Form 4, code M).
Other insiders filing for Denali Therapeutics Inc. (DNLI)
- Chin Peter Scott, Chief Medical Officer
- Thornberry Nancy, Director
- Schuth Alexander O., COFO and Secretary
- Watts Ryan J., President and CEO
- FLATLEY JAY T, Director
- Krognes Steve E., Director